Pazopanib in the Treatment of Bone Sarcomas: Clinical Experience.
Journal
Translational oncology
ISSN: 1936-5233
Titre abrégé: Transl Oncol
Pays: United States
ID NLM: 101472619
Informations de publication
Date de publication:
Feb 2020
Feb 2020
Historique:
received:
18
07
2019
revised:
26
11
2019
accepted:
01
12
2019
pubmed:
26
12
2019
medline:
26
12
2019
entrez:
26
12
2019
Statut:
ppublish
Résumé
The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy. All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed. Nineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity. Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
Sections du résumé
BACKGROUND
BACKGROUND
The effect of chemotherapy in metastatic bone sarcomas is poor and the condition is invariably fatal. Therefore, new treatment modalities are intensely needed. Pazopanib is a selective multitargeted tyrosine kinase inhibitor that has proven to be effective in the treatment of metastatic soft tissue sarcomas. The objective of this study was to evaluate the off-label use of pazopanib in patients with metastatic bone sarcomas who failed standard chemotherapy.
METHODS
METHODS
All patients with metastatic bone sarcomas treated with pazopanib between October 1st, 2011 and October 1st, 2017 at the Department of Oncology, Aarhus University Hospital were evaluated. Demographics, treatment, and survival outcomes were collected and analyzed.
RESULTS
RESULTS
Nineteen patients were identified. The median age was 38 years (range 18-62). Most of the patients (50%) were diagnosed with osteosarcoma. All patients had documented disease progression at the time of initiating pazopanib treatment. The median overall survival was 11 months. Median progression free survival was 5.4 months. Out of 19 patients, 13 (68%) had either partial response or stable disease. In five patients, the dose of pazopanib was reduced because of toxicity.
CONCLUSION
CONCLUSIONS
Off-label use of pazopanib is effective in the treatment of metastatic bone sarcomas of different histologies. Pazopanib was well tolerated in the treatment of patients with refractory bone sarcomas. Studies examining the effect of pazopanib alone or in combination with chemotherapy or other targeted therapies are needed.
Identifiants
pubmed: 31875575
pii: S1936-5233(19)30407-3
doi: 10.1016/j.tranon.2019.12.001
pmc: PMC6931211
pii:
doi:
Types de publication
Journal Article
Langues
eng
Pagination
295-299Informations de copyright
Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Med Oncol. 2018 Aug 16;35(10):126
pubmed: 30116912
Acta Oncol. 2014 Oct;53(10):1451-4
pubmed: 25143189
Med Sci (Basel). 2019 Mar 18;7(3):
pubmed: 30889920
Cancer. 2009 Nov 15;115(22):5243-50
pubmed: 19670450
Crit Rev Oncol Hematol. 2011 Mar;77(3):163-71
pubmed: 20456972
Cancer. 2008 May 15;112(10):2119-29
pubmed: 18338812
Clin Epidemiol. 2013 Mar 06;5:45-56
pubmed: 23687450
Cancer. 2015 Sep 1;121(17):2933-41
pubmed: 26033286
Lancet Oncol. 2015 Jan;16(1):98-107
pubmed: 25498219
Ann Oncol. 2014 Sep;25 Suppl 3:iii113-23
pubmed: 25210081
Acta Oncol. 2019 Jan;58(1):124-128
pubmed: 30207179
J Natl Cancer Inst. 2014 Oct 18;106(11):
pubmed: 25326640
ISRN Oncol. 2012;2012:896202
pubmed: 23304555
Ann Oncol. 2019 Feb 1;30(2):317-324
pubmed: 30428063
J Clin Oncol. 2010 Dec 10;28(35):5174-81
pubmed: 21060028
Acta Oncol. 2015 Jul;54(7):1063-4
pubmed: 25345493
Lancet Oncol. 2019 Jan;20(1):120-133
pubmed: 30477937
Lancet. 2012 May 19;379(9829):1879-86
pubmed: 22595799
Clin Cancer Res. 2010 Jan 15;16(2):530-40
pubmed: 20068094
Clin Cancer Res. 2002 Nov;8(11):3584-91
pubmed: 12429650
J Clin Oncol. 2003 May 15;21(10):2011-8
pubmed: 12743156
Anticancer Res. 2005 Mar-Apr;25(2A):955-7
pubmed: 15868933
Ann Oncol. 2012 Feb;23(2):508-16
pubmed: 21527590